NCT05043051

Autoimmune Basis for Postural Tachycardia Syndrome

Active, enrolled NA Last updated 8 April 2026

What this trial tests

NA trial testing Vagal stimulation in Postural Tachycardia Syndrome in 80 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

14 January 2022

Primary endpoint
28 February 2026

31 July 2026

Quick facts

Lead sponsor	University of Oklahoma
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	80
Start date	14 January 2022
Primary completion	28 February 2026
Estimated completion	31 July 2026
Sites	1 location across United States

Drugs / interventions tested

• Vagal stimulation
• Sham stimulation

Conditions studied

• Postural Tachycardia Syndrome — all drugs for Postural Tachycardia Syndrome →

Sponsor

University of Oklahoma

Who can join

Adults 18 to 80, any sex, with Postural Tachycardia Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune reaction will cause symptoms of autonomic dysfunction in some patients with postural tachycardia syndrome (POTS). The investigators further hypothesize that electrical stimulation of the vagus nerve will improve POTS symptoms, autoimmunity and inflammation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome: A Randomized Clinical Trial.
   Stavrakis S, Chakraborty P, Farhat K, Whyte S, et al · · 2024 · cited 38× · PMID 37999672 · DOI 10.1016/j.jacep.2023.10.015
2. Low-level tragus stimulation improves autoantibody-induced hyperadrenergic postural tachycardia syndrome in rabbits.
   Guo Y, Li H, Deng J, Zhang G, et al · · 2023 · cited 7× · PMID 36873318 · DOI 10.1016/j.hroo.2022.12.001